Litigation (Tables)

12 Months Ended

Dec. 31, 2021

Commitments and Contingencies Disclosure [Abstract]

Schedule of patent expiration

n February 2021, we received a Paragraph IV certification notice letter from ANI indicating that ANI submitted an abbreviated new drug application (ANDA) to the FDA to market a generic version of Orenitram before the expiration of the following patents:

U.S. Patent No.	Expiration Date
8,252,839	May 2024
9,050,311	May 2024
9,278,901	May 2024
7,544,713	July 2024
7,417,070	July 2026
8,497,393	December 2028
9,604,901	December 2028
9,592,066	December 2028
8,747,897	October 2029
8,410,169	February 2030
8,349,892	January 2031